Treating posttransplantation diabetes mellitus

Bibliography

• Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006;82:603-11
   PubMed Web of Science ®Google Scholar
• Jardine AG, Gaston RS, Fellstrom BC, et al. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011;378:1419-27
   PubMed Web of Science ®Google Scholar
• Sharif A, Hecking M, de Vries PJ, et al. Proceedings from an international consensus meeting on post-transplantation diabetes mellitus: recommendations and future directions. Am J Transplant 2014;14:1992-2000
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37(Suppl 1):S81-90
   PubMed Web of Science ®Google Scholar
• Davidson JA, Wilkinson A. New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist’s view. Diabetes Care 2004;27:805-12
   PubMed Web of Science ®Google Scholar
• Hornum M, Jorgensen KA, Hansen JM, et al. New-onset diabetes mellitus after kidney transplantation in Denmark. Clin J Am Soc Nephrol 2010;5:709-16
   PubMed Web of Science ®Google Scholar
• Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72:1066-72
   PubMed Web of Science ®Google Scholar
• Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64:979-83
   PubMed Web of Science ®Google Scholar
• Knobler H, Stagnaro-Green A, Wallenstein S, et al. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998;26:30-3
   PubMed Web of Science ®Google Scholar
• Werzowa J, Hecking M, Haidinger M, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 2013;95(3):456-62
   PubMed Web of Science ®Google Scholar
• Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-14
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-85
   PubMed Web of Science ®Google Scholar
• Ghisdal L, Van LS, Abramowicz MJ, et al. New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care 2012;35:181-8
   PubMed Web of Science ®Google Scholar
• Collins AJ, Foley RN, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease& end-stage renal disease in the United States. Am J Kidney Dis 2012;59(1 Suppl 1):A7; e1–420
   PubMedGoogle Scholar
• Valderhaug TG, Jenssen T, Hartmann A, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009;88:429-34
   PubMed Web of Science ®Google Scholar
• Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: an underdiagnosed phenomenon. Transplantation 2006;82:1667-72
   PubMed Web of Science ®Google Scholar
• Armstrong KA, Prins JB, Beller EM, et al. Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol 2006;1:100-8
   PubMed Web of Science ®Google Scholar
• Eide IA, Halden TA, Hartmann A, et al. Limitations of hemoglobin A1c for the diagnosis of posttransplant diabetes mellitus. Transplantation 2015;99:629-35
   PubMed Web of Science ®Google Scholar
• Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008;3:814-21
   PubMed Web of Science ®Google Scholar
• Ganji MR, Charkhchian M, Hakemi M, et al. Association of hyperglycemia on allograft function in the early period after renal transplantation. Transplant Proc 2007;39:852-4
   PubMed Web of Science ®Google Scholar
• Hosseini MS, Nemati E, Pourfarziani V, et al. Early hyperglycemia after allogenic kidney transplantation: does it induce infections. Ann Transplant 2007;12:23-6
   PubMed Web of Science ®Google Scholar
• Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003;3:590-8
   PubMed Web of Science ®Google Scholar
• Bergrem HA, Valderhaug TG, Hartmann A, et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol 2010;5:616-22
   PubMed Web of Science ®Google Scholar
• Caillard S, Eprinchard L, Perrin P, et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematics screening by oral glucose tolerance test. Transplantation 2011;91:757-64
   PubMedGoogle Scholar
• Cosio FG, Kudva Y, Van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005;67:2415-21
   PubMed Web of Science ®Google Scholar
• Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001;59:732-7
   PubMed Web of Science ®Google Scholar
• Baid S, Cosimi AB, Farrell ML, et al. Post-transplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72:1066-72
   PubMed Web of Science ®Google Scholar
• Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002;13:1374-80
   PubMed Web of Science ®Google Scholar
• Van Laecke LS, Van Biesen BW, Verbeke F, et al. Post-transplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009;9:2140-9
   PubMed Web of Science ®Google Scholar
• Bayer ND, Cochetti PT, Anil Kumar MS, et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010;90:861-6
   PubMed Web of Science ®Google Scholar
• Porrini E, Delgado P, Alvarez A, et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant 2008;23:1436-41
   PubMed Web of Science ®Google Scholar
• Kim YG, Ihm CG, Lee TW, et al. Association of genetic polymorphisms of interleukins with new-onset diabetes after transplantation in renal transplantation. Transplantation 2012;93:900-7
   PubMed Web of Science ®Google Scholar
• Tavira B, Coto E, Torres A, et al. Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with tacrolimus. Mol Genet Metab 2012;105:525-7
   PubMed Web of Science ®Google Scholar
• Sharif A, Baboolal K. Risk factors for new-onset diabetes after kidney transplantation. Nat Rev Nephrol 2010;6:415-23
   PubMed Web of Science ®Google Scholar
• Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008;3:814-21
   PubMed Web of Science ®Google Scholar
• Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclosporine as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005;331:810-21
   PubMed Web of Science ®Google Scholar
• Ghisdal L, Bouchta NB, Broeders N, et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008;21:146-51
   PubMed Web of Science ®Google Scholar
• Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-18
   PubMed Web of Science ®Google Scholar
• Murakami N, Riella LV, Funakoshi T. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant 2014;14(10):2317-27
   PubMed Web of Science ®Google Scholar
• Pascual J, Zamora J, Galeano C, et al. Steroid withdrawal or avoidance for kidney transplant recipients (Review). Cochrane Database Syst Rev 2009;1:CD005632
   Google Scholar
• Pascual J, Royuela A, Galeano C, et al. Very early steroidwithdrawal or complete avoidance for kidney transplant recipients:A systematic review. Nephrol Dial Transplant 2012;27:825-32
   PubMed Web of Science ®Google Scholar
• Pascual J, Galeano C, Royuela A, et al. A systematic reviewon steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 2010;90:343-9
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011;91:976-83
   PubMed Web of Science ®Google Scholar
• van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67
   PubMed Web of Science ®Google Scholar
• Luan FL, Steffick DE, Gadegbeku C, et al. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant 2009;9:160-8
   PubMedGoogle Scholar
• U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Volume 2 Fig 7.27 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2013. p. 291
   Google Scholar
• Hjelmesaeth J, Hartmann A, Kofstad J, et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001;16:829-35
   PubMed Web of Science ®Google Scholar
• Christiansen E, Andersen HB, Rasmussen K, et al. Pancreatic beta-cell function and glucose metabolism in human segmental pancreas and kidney transplantation. Am J Physiol 1993;264(3 Pt 1):E441-9
   PubMedGoogle Scholar
• Goldstein RE, Wasserman DH, McGuinness OP, et al. Effects of chronic elevation in plasma cortisol on hepatic carbohydrate metabolism. Am J Physiol 1993;264(1 Pt 1):E119-27
   PubMedGoogle Scholar
• Duijnhoven EM, Boots JM, Christiaans MH, et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001;12(3):583-8
   PubMed Web of Science ®Google Scholar
• van Hooff JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 2004;19(Suppl 6):vi8-vi12
   PubMedGoogle Scholar
• Luan FL, Zhang H, Schaubel DE, et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. Am J Transplant 2008;8:1871-7
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. Exploring treatment strategies for type 2 diabetes. Diabetes Care 2007;30:2737-45
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218
   PubMed Web of Science ®Google Scholar
• Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028-32
   PubMed Web of Science ®Google Scholar
• Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-60
   PubMed Web of Science ®Google Scholar
• Luan FL, Steffick DE, Ojo AO. Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Kidney Int 2009;76:825-30
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155
   PubMed Web of Science ®Google Scholar
• Joss N, Staatz CE, Thomson AH, Jardine AG. Predictors of new onset diabetes after renal transplantation. Clin Transplant 2007;21:136-43
   PubMed Web of Science ®Google Scholar
• Yale JF, Roy RD, Grose M, et al. Effects of cyclosporine on glucose tolerance in the rat. Diabetes 1985;34:1309-13
   PubMed Web of Science ®Google Scholar
• Caro JF, Amatruda JM. Glucocorticoid-induced insulin resistance: the importance of postbinding events in the regulation of insulin binding, action, and degradation in freshly isolated and primary cultures of rat hepatocytes. J Clin Invest 1982;69:866-75
   PubMed Web of Science ®Google Scholar
• Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012;23:739-49
   PubMed Web of Science ®Google Scholar
• Hecking M, Werzowa J, Haidinger M, et al. European-New-Onset Diabetes After Transplantation Working Group. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant 2013;28:550-66
   PubMed Web of Science ®Google Scholar
• Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008;85:353-8
   PubMed Web of Science ®Google Scholar
• Yates CJ, Fourlanos S, Hjelmesaeth J, et al. New-onset diabetes after kidney transplantation-changes and challenges. Am J Transplant 2012;12:820-8
   PubMed Web of Science ®Google Scholar
• Therasse A, Wallia A, Molitch ME. Management of post-transplant diabetes. Curr Diab Rep 2013;13:121-9
   PubMed Web of Science ®Google Scholar
• Meah F, Juneja R. Insulin tactics in Type 2 Diabetes. Med Clin North Am 2015;99:157-86
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care 2014;37(Suppl 1):S14-80
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm. Endocr Pract 2013;19:327-36
   PubMed Web of Science ®Google Scholar
• Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Transplantation 2003;75(10 Suppl):ss3-24
   PubMedGoogle Scholar
• Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant 2011;11:1376-81
   PubMed Web of Science ®Google Scholar
• Lalau JD, Arnouts P, Sharif A, De Broe ME. Metformin and other antidiabetic agents in renal failure patients. Kidney Int 2015;87(2):308-22
   PubMed Web of Science ®Google Scholar
• Sarno G, Muscogiuri G, De Rosa P. New-onset diabetes after kidney transplantation: prevalence, risk factors, and management. Transplantation 2012;93:1189-95
   PubMed Web of Science ®Google Scholar
• Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract 2008;14:979-84
   PubMedGoogle Scholar
• Wissing KM, Pipeleers L. Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment. Transplant Rev 2014;28:37-46
   Web of Science ®Google Scholar
• Stevens KK, Patel RK, Jardine AG. How to identify and manage diabetes mellitus after renal transplantation. J Ren Care 2012;38(Suppl 1):125-37
   PubMedGoogle Scholar
• Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis 2014;64:510-33
   PubMed Web of Science ®Google Scholar
• Luther P, Baldwin DJr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004;4:2135-8
   PubMed Web of Science ®Google Scholar
• Werzowa J, Hecking M, Haidinger M, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 2013;95:456-62
   PubMed Web of Science ®Google Scholar
• Pietruck F, Kribben A, Van TN, et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 2005;18:483-6
   PubMed Web of Science ®Google Scholar
• Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 2005;80:1402-5
   PubMed Web of Science ®Google Scholar
• Juan Khong M, Ping Chong Ch. Prevention and management of new-onset diabetes mellitus in kidney transplantation. Neth J Med 2014;72:127-34
   PubMed Web of Science ®Google Scholar
• Voytovich MH, Haukereid C, Hjelmesaeth J, et al. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients. Clin Transplant 2007;21:246-51
   PubMed Web of Science ®Google Scholar
• Türk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006;6:842-6
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005;78:388-99
   PubMed Web of Science ®Google Scholar
• D’Amico E, Hui H, Khoury N, et al. Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs. J Mol Endocrinol 2005;34:377-90
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonist on renal function. World J Diabetes 2013;4(5):190-201
   PubMedGoogle Scholar
• Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation–a randomized, double-blind, placebo-controlled trial. Am J Transplant 2014;14:115-23
   PubMed Web of Science ®Google Scholar
• Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol 2014;2014:617638
   PubMed Web of Science ®Google Scholar
• Strøm Halden TA, Åsberg A, Vik K, et al. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant 2014;29:926-33
   PubMed Web of Science ®Google Scholar
• Pinelli NR, Nemerovski CW, Koelling TM. Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report. Transplant Proc 2011;43:2113-15
   PubMed Web of Science ®Google Scholar
• Lane JT, Odegaard DE, Haire CE, et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011;92:e56-7
   PubMed Web of Science ®Google Scholar
• Sanyal D, Gupta S, Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. Indian J Endocrinol Metab 2013;17(Suppl 1):S203-5
   PubMedGoogle Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014;16:1016-27
   PubMed Web of Science ®Google Scholar
• Halimi S, Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab 2014;40(6 Suppl 1):S28-34
   PubMedGoogle Scholar